Controversial Bill to Reintroduce “Bee Killer” Pesticides Faces Scrutiny

The Conference of Presidents of the National Assembly is poised to place Senator laurent Duplomb’s (LR) bill on the Assembly’s agenda, possibly leading to a public debate scheduled from May 26th to 28th. prior to this, the bill will undergo review by the Lasting Development Committee (focusing on articles 5 and 6 from May 6th) and the Economic Affairs Committee (examining the remainder of the text from May 13th).

Undermining Health and Ecosystems: The Core Concerns

At its heart, the bill proposes a return to the use of neonicotinoid insecticides, often referred to as “bee killers,” under specific conditions. This move has sparked considerable controversy, with critics arguing it prioritizes agricultural production over environmental and public health concerns.

A key point of contention lies in the proposed prioritization of ANSES‘ (French Agency for Food, Environmental and Occupational Health & Safety) work. The bill suggests focusing on a list of priority uses based solely on their impact on production potential and the availability of alternatives. This approach, critics argue, could relegate substances harmful to health and the environment to a lower priority, delaying their assessment and potentially exposing the public and ecosystems to unneeded risks.

Moreover, the bill seeks to strengthen the position of pesticide manufacturers by granting them the chance to submit written observations before a rejection decision is made. This provision is viewed by some as redundant, given that European pesticide authorization processes already incorporate academic literature and scientific data.

Neonicotinoids: A Threat to Bees and Human Health

Neonicotinoids (NNIs) are a class of insecticides that share a common mode of action: they target the central nervous system of insects, binding to nicotinic acetylcholine receptors, ultimately leading to paralysis and death. Their use has been progressively restricted at the European level as scientific understanding of their harmful effects, particularly on bee populations, has grown. Currently, only acetamipride, sulfoxaflor, and flupyradifurone remain authorized for use in europe.

France, recognizing the threat to both human health and ecosystems, made a commendable decision to ban all neonicotinoids in 2016, followed by a reinforced ban in 2018. This decision was grounded in a wealth of scientific evidence demonstrating the detrimental impacts of these substances.

Recent findings from the european Food Safety Authority (EFSA) in 2024 highlight that acetamipride poses a risk to human health, specifically raising concerns regarding developmental neurotoxicity. As early as 2022, EFSA was prompted to evaluate the endocrine-disrupting potential of this substance, effects that are also well-documented in scientific literature. The European Commission has requested EFSA to re-evaluate acetamipride considering these concerns.

Similarly, the endocrine-disrupting potential of Flupyradifurone has never been fully assessed according to guidelines available since 2018. This lack of thorough evaluation raises serious questions about its safety.

Moreover, products containing sulfoxaflor have been subject to recent legal challenges due to insufficient and concrete evaluations of their long-term impacts on bee populations.

Despite this compelling evidence, the French government is considering lifting the ban on these substances, a move that has drawn sharp criticism from environmental and public health advocates.

Ethical Concerns and Scientific Independence Under Scrutiny

ANSES’ ethics committee, tasked with preventing conflicts of interest, has issued a warning about the potential risks associated with this bill in an opinion dated April 10th.This warning echoes concerns raised by the National Health Conference, which cautions against any actions that could compromise the independence of scientific expertise.

Call to Action

The potential reversal of the neonicotinoid ban raises significant concerns about the prioritization of short-term economic gains over long-term environmental and public health. the debate surrounding this bill underscores the importance of robust scientific evaluation, autonomous risk assessment, and a commitment to protecting both human health and the delicate balance of our ecosystems.